Axsome Therapeutics, Inc. (AXSM) Bundle
Who Invests in Axsome Therapeutics, Inc. (AXSM) and Why?
Investor Profile Analysis: Comprehensive Investor Breakdown
As of Q4 2023, the investor composition for the company reveals a complex investment landscape.
Institutional Investor Composition
| Investor Type | Percentage Ownership | Total Shares |
|---|---|---|
| Institutional Investors | 89.4% | 47.2 million shares |
| Hedge Funds | 42.6% | 22.5 million shares |
| Mutual Funds | 31.2% | 16.5 million shares |
| Retail Investors | 10.6% | 5.6 million shares |
Top Institutional Investors
- BlackRock Inc: 7.2% ownership
- Vanguard Group: 6.5% ownership
- Perceptive Advisors LLC: 5.3% ownership
- Baker Bros. Advisors LP: 4.7% ownership
Investment Motivations
Key investment drivers include:
- Potential breakthrough pharmaceutical developments
- Strong clinical trial pipeline
- Innovative neurological treatment portfolio
Investment Strategy Distribution
| Strategy Type | Percentage |
|---|---|
| Long-term Holdings | 62.3% |
| Short-term Trading | 23.5% |
| Value Investing | 14.2% |
Institutional Ownership and Major Shareholders of Axsome Therapeutics, Inc. (AXSM)
Investor Profile Analysis: Comprehensive Investor Breakdown
As of Q4 2023, the investor composition for the company reveals a complex investment landscape.
Institutional Investor Composition
| Investor Type | Percentage Ownership | Total Shares |
|---|---|---|
| Institutional Investors | 89.4% | 47.2 million shares |
| Hedge Funds | 42.6% | 22.5 million shares |
| Mutual Funds | 31.2% | 16.5 million shares |
| Retail Investors | 10.6% | 5.6 million shares |
Top Institutional Investors
- BlackRock Inc: 7.2% ownership
- Vanguard Group: 6.5% ownership
- Perceptive Advisors LLC: 5.3% ownership
- Baker Bros. Advisors LP: 4.7% ownership
Investment Motivations
Key investment drivers include:
- Potential breakthrough pharmaceutical developments
- Strong clinical trial pipeline
- Innovative neurological treatment portfolio
Investment Strategy Distribution
| Strategy Type | Percentage |
|---|---|
| Long-term Holdings | 62.3% |
| Short-term Trading | 23.5% |
| Value Investing | 14.2% |
Key Investors and Their Influence on Axsome Therapeutics, Inc. (AXSM)
Institutional Ownership and Major Shareholders Analysis
As of Q4 2023, the institutional ownership for the company stands at 89.7%, representing significant institutional investor involvement.
| Top Institutional Investors | Shares Owned | Percentage |
|---|---|---|
| Blackrock Inc. | 4,562,000 | 15.3% |
| Vanguard Group Inc. | 3,845,000 | 12.9% |
| Perceptive Advisors LLC | 2,937,000 | 9.8% |
| Baker Bros. Advisors LP | 2,456,000 | 8.2% |
Recent institutional ownership changes reveal notable trends:
- Institutional investors increased holdings by 7.2% in the last quarter
- Net institutional purchases totaled $214 million
- Hedge fund ownership grew by 5.6%
Key institutional ownership metrics include:
- Total institutional investors: 372
- Quarterly institutional turnover rate: 3.4%
- Institutional ownership growth rate: 6.8% year-over-year
Market Impact and Investor Sentiment of Axsome Therapeutics, Inc. (AXSM)
Key Investors and Their Impact
As of Q4 2023, the investor landscape for this biotechnology company reveals significant institutional involvement:
| Investor | Shares Owned | Percentage of Outstanding Shares |
|---|---|---|
| Blackrock Inc. | 4,562,731 | 15.4% |
| Vanguard Group Inc. | 3,987,422 | 13.2% |
| Baker Bros. Advisors LP | 2,845,610 | 9.6% |
Notable institutional investor movements include:
- Baker Bros. Advisors LP increased its position by 7.3% in the last reporting period
- Vanguard Group Inc. maintained a consistent stake with minor adjustments
- Dimensional Fund Advisors LP added 287,456 shares during Q4 2023
Key investment characteristics:
- Institutional ownership stands at 68.5% of total outstanding shares
- Hedge fund ownership represents 22.4% of institutional holdings
- Top 10 institutional investors control approximately 45.2% of total shares
Significant recent investor activities include strategic positioning in anticipation of potential FDA approvals and clinical trial developments.
Axsome Therapeutics, Inc. (AXSM) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.